|
Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs.(Research)
Emerging Infectious Diseases
|
April 1, 2004|
|
COPYRIGHT 2004 U.S. National Center for Infectious Diseases. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group.
(Hide copyright information)
Copyright
|
Severe acute respiratory syndrome (SARS) is an infectious disease caused by a newly identified human coronavirus (SARS-CoV). Currently, no effective drug exists to treat SARS-CoV infection. In this study, we investigated whether a panel of commercially available antiviral drugs exhibit in vitro anti-SARS-CoV activity. A drug-screening assay that scores for virus-induced cytopathic effects on cultured cells was used. Tested were 19 clinically approved compounds from several major antiviral pharmacologic classes: nucleoside analogs, interferons, protease inhibitors, reverse ...
Find more facts and information related to the
article "Inhibition of SARS coronavirus infection in vitro ..."